美国C3肾小球病患者的真实世界分析
基于美国电子健康记录的真实世界回顾性队列纳入260例C3肾小球病(C3G)患者,平均年龄47.8岁,中位随访2.1年,多数诊断时已处CKD≥3期(56.6%)且伴蛋白尿(54.4%);可评估者中59.0%进展至更高CKD分期、26.0%进展至CKD 5期或肾衰竭。
要点
- C3G诊断时多数已存在晚期肾病(CKD≥3期占56.6%)与蛋白尿(54.4%)。
- 可评估患者中59.0%进展至更高CKD分期,26.0%进展至CKD 5期或肾衰竭。
- 移植后复发C3G报告27例(10.4%),提示需关注移植人群复发风险。
核心结论
- 美国真实世界C3G患者诊断时多已存在晚期肾病且CKD分期进展率高,提示需采用新型治疗改善结局。
研究设计与样本
- 回顾性队列研究,利用电子健康记录识别年龄≥12岁、有C3G诊断且基线连续临床活动≥12个月、随访≥6个月的患者。
- 共纳入260例C3G患者,按既往肾移植状态、随访期间CKD分期进展及基线血清C3水平分层。
- CKD分期进展仅在索引时CKD 1至4期且有足够数据评估进展的患者中分析。
主要发现
- 260例患者中女性占51.9%,平均(SD)年龄47.8(20.6)岁,中位随访2.1年。
- 可评估患者中诊断时CKD≥3期占56.6%,蛋白尿占54.4%。
- 移植后复发C3G报告27例(10.4%)。
- 可评估CKD分期进展的患者中,102例(59.0%)进展至更高CKD分期,45例(26.0%)进展至CKD 5期或肾衰竭。
- 进展至更高CKD分期的中位时间为14.9个月,进展至CKD 5期或肾衰竭的中位时间不可估计(NE)。
临床怎么用
- 临床应关注C3G患者诊断时即可能存在晚期肾病与蛋白尿,需早期识别并密切监测CKD分期进展。
- 对C3G患者需评估肾移植后复发风险,随访中注意CKD分期变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: C3 glomerulopathy (C3G) is a rare kidney disease caused by alternative pathway (AP) overactivation. This analysis describes demographic and clinical characteristics of patients with C3G in the United States (US) and evaluates chronic kidney disease (CKD) stage progression. METHODS: This retrospective cohort study used electronic health records (EHRs) to identify patients aged ≥ 12 years with a C3G diagnosis (index) and with continuous clinical activity ≥ 12 months before (baseline) and ≥ 6 months after index (follow-up; until death or data end). Patients were stratified by prior kidney transplant status, CKD stage progression during follow-up, and baseline serum C3 level. CKD stage progression was assessed in patients with CKD stages 1 to 4 (at index) and adequate data to assess progression during follow-up. RESULTS: Overall, 260 patients with C3G were identified: 51.9% were female; mean (SD) age was 47.8 (20.6) years; median follow-up was 2.1 years. Of those assessed, most had CKD stage ≥ 3 (56.6%) and proteinuria (54.4%) at index. Posttransplant recurrent C3G was reported in 27 patients (10.4%). Of those assessed for CKD stage progression, 102 (59.0%) and 45 (26.0%) progressed to a higher CKD stage or CKD stage 5 or kidney failure, respectively. Median time to progression of CKD stage or to stage 5 or kidney failure was 14.9 months and not estimable (NE), respectively. CONCLUSION: In a real-world US population of patients with C3G, we identified a population with both advanced kidney disease around the time of diagnosis and high rates of CKD stage progression, highlighting the need to utilize novel treatments to improve patient outcomes.
引用
- Ndife BC, Aldworth C, Nguyen J, et al. Real-World Analysis of Patients With C3 Glomerulopathy in the United States. Kidney Int Rep. 2026. PMID: 41716735. doi:10.1016/j.ekir.2026.103773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。